Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
|
Nature
|
2007
|
17.68
|
2
|
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
|
Cancer Cell
|
2002
|
11.83
|
3
|
Treatment of acute lymphoblastic leukemia.
|
N Engl J Med
|
2006
|
11.30
|
4
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
5
|
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
|
Nature
|
2008
|
10.12
|
6
|
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
|
Nature
|
2012
|
9.89
|
7
|
Acute lymphoblastic leukaemia.
|
Lancet
|
2008
|
8.54
|
8
|
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
|
N Engl J Med
|
2009
|
7.95
|
9
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
10
|
CREST maps somatic structural variation in cancer genomes with base-pair resolution.
|
Nat Methods
|
2011
|
5.34
|
11
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
12
|
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
|
Lancet Oncol
|
2009
|
4.89
|
13
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
14
|
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
4.35
|
15
|
Germline Mutations in Predisposition Genes in Pediatric Cancer.
|
N Engl J Med
|
2015
|
4.27
|
16
|
CREBBP mutations in relapsed acute lymphoblastic leukaemia.
|
Nature
|
2011
|
3.72
|
17
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
18
|
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
|
Blood
|
2012
|
2.82
|
19
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
20
|
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.
|
Blood
|
2009
|
2.70
|
21
|
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
|
Blood
|
2012
|
2.55
|
22
|
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
|
Genome Res
|
2011
|
2.52
|
23
|
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
|
Blood
|
2010
|
2.37
|
24
|
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
|
Nat Genet
|
2015
|
2.34
|
25
|
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
|
J Clin Oncol
|
2008
|
2.29
|
26
|
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
|
J Clin Oncol
|
2009
|
2.20
|
27
|
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
|
JAMA
|
2015
|
2.20
|
28
|
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
|
Blood
|
2007
|
2.19
|
29
|
Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.
|
Lancet Oncol
|
2015
|
2.15
|
30
|
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
|
Blood
|
2012
|
2.14
|
31
|
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.
|
Cancer Cell
|
2010
|
2.09
|
32
|
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes.
|
Nat Genet
|
2005
|
1.94
|
33
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
34
|
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.
|
Blood
|
2008
|
1.89
|
35
|
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.88
|
36
|
Development and implementation of a pharmacist-managed clinical pharmacogenetics service.
|
Am J Health Syst Pharm
|
2011
|
1.85
|
37
|
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.
|
J Clin Oncol
|
2015
|
1.84
|
38
|
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
|
Clin Pharmacol Ther
|
2008
|
1.82
|
39
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
40
|
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.
|
Nat Genet
|
2003
|
1.79
|
41
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
42
|
New markers for minimal residual disease detection in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.78
|
43
|
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.
|
J Clin Oncol
|
2013
|
1.76
|
44
|
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
|
Lancet Oncol
|
2015
|
1.74
|
45
|
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
|
Blood
|
2011
|
1.68
|
46
|
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
|
Hum Mol Genet
|
2012
|
1.66
|
47
|
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
|
Leukemia
|
2004
|
1.65
|
48
|
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
|
J Clin Oncol
|
2011
|
1.60
|
49
|
Minimal residual disease in acute lymphoblastic leukemia.
|
Hematology Am Soc Hematol Educ Program
|
2010
|
1.57
|
50
|
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.
|
Ann Hematol
|
2004
|
1.57
|
51
|
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.
|
Blood
|
2015
|
1.57
|
52
|
Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia.
|
Pediatr Phys Ther
|
2014
|
1.53
|
53
|
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.47
|
54
|
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
|
J Clin Invest
|
2005
|
1.46
|
55
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
56
|
The Health Utilities Index 3 invalidated when completed by nurses for pediatric oncology patients.
|
Cancer Nurs
|
2007
|
1.43
|
57
|
Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.
|
Blood
|
2015
|
1.42
|
58
|
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.
|
J Natl Cancer Inst
|
2012
|
1.41
|
59
|
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
|
Blood
|
2006
|
1.41
|
60
|
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.
|
Blood
|
2006
|
1.40
|
61
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
62
|
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
|
PLoS Med
|
2008
|
1.37
|
63
|
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.
|
Nat Med
|
2011
|
1.34
|
64
|
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence.
|
Leukemia
|
2010
|
1.34
|
65
|
A 50-year journey to cure childhood acute lymphoblastic leukemia.
|
Semin Hematol
|
2013
|
1.32
|
66
|
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
|
J Clin Oncol
|
2014
|
1.31
|
67
|
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.28
|
68
|
PharmGKB summary: methotrexate pathway.
|
Pharmacogenet Genomics
|
2011
|
1.27
|
69
|
Attention and working memory abilities in children treated for acute lymphoblastic leukemia.
|
Cancer
|
2010
|
1.26
|
70
|
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
|
J Clin Oncol
|
2015
|
1.26
|
71
|
Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007.
|
J Clin Oncol
|
2012
|
1.25
|
72
|
Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma.
|
J Clin Oncol
|
2007
|
1.22
|
73
|
Genome-wide study of methotrexate clearance replicates SLCO1B1.
|
Blood
|
2012
|
1.17
|
74
|
Improved prognosis for older adolescents with acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.16
|
75
|
Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia.
|
Cancer
|
2007
|
1.16
|
76
|
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
|
Clin Cancer Res
|
2012
|
1.15
|
77
|
Recent research advances in childhood acute lymphoblastic leukemia.
|
J Formos Med Assoc
|
2010
|
1.15
|
78
|
Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis.
|
Pediatr Blood Cancer
|
2005
|
1.14
|
79
|
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.14
|
80
|
Functional characterization of liver enhancers that regulate drug-associated transporters.
|
Clin Pharmacol Ther
|
2011
|
1.14
|
81
|
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2014
|
1.10
|
82
|
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
|
Leukemia
|
2012
|
1.10
|
83
|
Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2013
|
1.10
|
84
|
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
|
Leukemia
|
2011
|
1.08
|
85
|
IDH1 and IDH2 mutations in pediatric acute leukemia.
|
Leukemia
|
2011
|
1.08
|
86
|
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1.
|
Leukemia
|
2009
|
1.07
|
87
|
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
|
PLoS Comput Biol
|
2010
|
1.07
|
88
|
Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2008
|
1.06
|
89
|
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
|
Blood
|
2014
|
1.04
|
90
|
Typhlitis in childhood cancer.
|
Cancer
|
2005
|
1.04
|
91
|
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
|
Leukemia
|
2010
|
1.03
|
92
|
MRI of knee osteonecrosis in children with leukemia and lymphoma: Part 2, clinical and imaging patterns.
|
AJR Am J Roentgenol
|
2006
|
1.02
|
93
|
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells.
|
Nat Genet
|
2015
|
1.02
|
94
|
Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression.
|
Blood
|
2011
|
1.00
|
95
|
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
|
Cancer
|
2012
|
0.99
|
96
|
Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia.
|
Phys Ther
|
2008
|
0.99
|
97
|
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.
|
Blood
|
2004
|
0.98
|
98
|
A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.
|
Pharmacogenetics
|
2004
|
0.96
|
99
|
Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia.
|
Pediatr Blood Cancer
|
2011
|
0.96
|
100
|
Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia.
|
AJNR Am J Neuroradiol
|
2009
|
0.96
|